We are a clinical-stage biotechnology company developing novel therapeutics to meet the growing global need for effective, safe antiviral treatments. We employ a unique structure-based drug discovery technology platform and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. Our antivirals target the replication process and are designed to be safe, broad-spectrum, resistant and convenient to administer.

We are quickly and efficiently advancing multiple programs with clinical development underway for influenza, norovirus and coronaviruses, while also discovering and developing antiviral compounds for other high-value indications.

Nasdaq Bell Ringing Ceremony

Home
Investors
Company Information
Contacts

Contacts

Alliance Advisors IR
Jody Cain
T: 310-691-7100
Jcain@allianceadvisors.com

Equity Stock Transfer
237 W 37th St
#601
New York, NY 10018
info@equitystock.com
www.equitystock.com

Weinberg & Company, P.A.
www.weinbergla.com

Contacts

Investor Relations

Transfer Agent

Auditor

Sign Up for Email Alerts